Introduction {#S1}
============

Depression is referred to as the "common cold" of the 21^st^ century \[[@ref1]\]. We can understand this expression twofold. On the one hand, it emphasises the prevalence of disease symptoms in the modern world, while on the other hand it points to the immunological background of depressive disorders \[[@ref2]\]. Over the past 40 years, many attempts have been made to understand the biological causes of depressive symptoms. In the 1990s, monoamine theories seemed to be the gold standard, exploited by the pharmaceutical industry \[[@ref3]\]. Over the years, however, they have proven to be insufficient and depression has become an increasingly common disease in all age groups \[[@ref4], [@ref5]\].

A new understanding of mood disorders, including depressive disorders, has emerged over the past three decades. Depression is conceptualized as an immune-inflammatory and oxidative stress disorder associated with neuroprogressive changes as a consequence of peripherally activated immune-inflammatory pathways, including peripheral cytokines and immune cells which penetrate into the brain via the blood barrier \[[@ref6], [@ref7]\], as well as nitro-oxidative stress and antioxidant imbalances \[[@ref8], [@ref9]\].

In the neurodevelopmental theory of depression, Gałecki and Talarowska \[[@ref10]\] emphasised the importance of the earliest stages of our lives for the formation of personality traits conducive to the occurrence of a depressive episode in adult life. Human personality is a collection of typical interpersonal behaviours, subjective reactions, feelings and goals we strive for, conditioned by the functioning of branched networks of nervous connections \[[@ref11]\]. Among the features of mental structure conducive to the appearance of depression, anxiety is mentioned as a permanent feature of functioning. According to Bukh *et al*. \[[@ref12]\], the presence of personality traits typical for the so-called Cluster C (avoidant, dependent and obsessive-compulsive personality) reduces the likelihood of achieving remission of depressive disorders by 30% and increases the risk of relapse after the first episode by as much as 80% \[[@ref12]\].

The aim of this study is to investigate whether personality traits predisposing to a depressive episode (hypochondria, dysthymic, hysteria) are associated with changes in peripheral gene expression for selected indicators of inflammation and oxidative balance (manganese superoxide dismutase (MnSOD), myeloperoxidase (MPO), cyclooxygenase 2 (COX-2), inducible nitric oxide synthase (iNOS), and metalloproteinases 2 and 9 (MMP-2, MMP-9).

We hypothesized that the severity of anxiety as a permanent personality trait and scales of the neurotic triad of the Minnesota Multiphasic Personality Inventory (MMPI-2) would be associated with an increased inflammatory response.

Material and methods {#S2}
====================

One hundred and four patients treated for recurrent depressive disorders were enrolled in the study (aged 20--60, average age (mean ± SD) 8.22 ±11.56). The criteria for inclusion in the study were based on the diagnostic criteria for an episode of depression and recurrent depressive disorders in accordance with the ICD-10 guidelines (F32.0-7.32.2, F33.0-F33.8) \[[@ref13]\].

The subjects took part in the study during hospitalisation. Participation in the experiment did not have an impact on the applied treatment modalities (pharmacotherapy, psychotherapy). All of the patients were treated with standard antidepressive therapy: SSRIs (selective serotonin reuptake inhibitors) in standard doses The specified agents were administered in therapeutic doses, defined by Ettinger \[[@ref14]\].

The criteria for exclusion from the trial included: history of treatment confirming psychiatric disorders other than depression in the past; presence of somatic diseases that may affect depression; trauma of the central nervous system; history of inflammatory, autoimmune and neoplastic diseases; abuse or addiction to psychoactive substances; lack of consent for participation in the trial. Qualification for participation in the experiment was performed at random without replacement sampling. All the subjects qualified for the study were native Poles from central Poland, not related to one another. Each patient gave written consent to participate in the experiment in accordance with the report approved by the Bioethics Committee of the Medical University of Lodz (approval no.: RNN/534/10/KB of 07/09/2010).

The examined subjects were divided and two groups were formed, i.e. patients diagnosed with the first episode of depression (ED-I, *n* = 34) and patients affected by a repeated episode of the disease (recurrent depressive episode, rDE, *n* = 70). No statistically significant differences were found between the examined groups in terms of age (*Z* = 0.117, *p* = 0.507) or sex (χ^2^ = 0.221, *p* = 0.641).

Assessment of depression severity {#S2_1}
---------------------------------

The Hamilton Depression Rating Scale (HDRS, HAM-D) \[[@ref15]\], was used to evaluate severity of depression. A scoring system developed by Demyttenaere and De Fruyt \[[@ref16]\] was applied when analysing the intensity of depressive episode symptoms.

Assessment of personality traits (the Minnesota Multiphasic Personality Inventory, MMPI-2) {#S2_2}
------------------------------------------------------------------------------------------

The personality structure of the examined individuals was assessed using the Polish version of the MMPI-2 test developed by S. Hathaway and J. McKinley, adapted by T. Kucharski \[[@ref17], [@ref18]\]. A detailed description of the MMPI-2 test was presented in one of our previous papers \[[@ref19], [@ref20]\].

In each case, an evaluation of the mental state, assessment of the severity of depressive disorders and assessment of performance of psychological tests were conducted by the same person, i.e. a clinical psychologist. An examination based on the application of the HDRS scale was performed twice, i.e. on the day of qualification of a specific person for the experiment and after clinical condition improvement (after 8 weeks of treatment on average). The examination with the MMPI-2 test took place after the patients were qualified to participate in the examination.

Assessment of expression at mRNA and protein levels {#S2_3}
---------------------------------------------------

The procedure of genetic analyses was described in detail in one of the papers by Talarowska *et al*. \[[@ref20]\]. The blood used to conduct genetic analyses was collected (in volumes of 5 ml) on the day of admission to the experiment.

Evaluation of selected genes' expression at the level of protein {#S2_4}
----------------------------------------------------------------

Total protein concentration in blood plasma of the patients was determined using the Micro BCA Protein Assay Kit (Thermo SCIENTIFIC) based on the manufacturer's recommendations. One hundred fifty µl of the reaction mixture was added to pits containing 150 µl of serum, diluted 10 times in 10 mM of phosphate buffered saline, pH 7.4, and incubated (2 h, 37°C). In order to measure protein concentration, an analytical curve for serum albumin was determined. Both the examined samples and the reference samples were made in parallel in three repetitions. Sample absorbance was measured using a Multiskan Ascent Microplate Photometer (Thermo Labsystems) at λ = 570 nm and total protein concentration was calculated from the standard curve equation.

Evaluation of selected genes' expression at the level of mRNA {#S2_5}
-------------------------------------------------------------

### Total RNA isolation {#S2_5_1}

Peripheral blood was used as a material in the genotype study (in volumes of 5 ml on EDTA). Total RNA isolation from the patients' blood samples using TRIZOL (Invitrogen Life Technologies) -- an RNA extraction reagent -- according to the standard acid-guanidinium-phenol-chloroform method, was performed using Chomczyński's modified method. The absorbance of isolated RNA was measured using a spectrophotometer (Picodrop) at λ = 260 nm with the aim of determining total RNA concentration. Isolated RNA was stored at a temperature of --70°C.

### Quality analysis of isolated RNA {#S2_5_2}

The quality of total RNA was checked with an Agilent RNA 6000 Nano Kit (Agilent Technologies) in accordance with the manufacturer's recommendations. 1 µl of RNA 6000 Nano dye was added to a test tube containing 65 µl of Agilent RNA 6000 Nano gel matrix, and then centrifuged (10 min, 13000 xg).The gel-fluorescent dye mixture was applied on the surface of a Nano chip placed in a workstation. Then, 5 µl of RNA Nano marker were added to selected pits. Isolated samples of RNA and RNA size marker were subject to denaturation (2 min, 70°C), and then 1 µl of the sample was pipetted to selected pits of the Nano chip, and mixed (1 min, 2400 rpm). The quality of isolated RNA was checked using a 2100 Bioanalyzer (Agilent Technologies). The level of degradation of total RNA was determined using an electrophoretogram and the RNA integrity number (RIN) values recorded. Only the samples with RIN values \> 7 were subject to further analysis.

A reverse transcription (RT) reaction was carried out using a TaqMan RNA Reverse Transcription Kit (Applied Biosystems) based on the manufacturer's recommendations. The samples were incubated (30 min, 16°C and 30 min, 42°C) in a thermocycler(Biometra). Reverse transcriptase was inactivated (5 min, 85°C) and the obtained cDNA was stored at a temperature of --20°C. A real-time PCR reaction was conducted using TaqMan Universal PCR Master Mix, No UNG (Applied Biosystems), according to the protocol provided by the manufacturer, delivered by Applied Biosystems. To calculate relative expression of miRNA genes, the *Ct* comparative method was used \[[@ref21], [@ref22]\].

Statistical analysis {#S2_6}
--------------------

Selected methods of descriptive statistics and methods of statistical reasoning were applied in the statistical analysis of the collected material. During statistical verification of the hypotheses, a two-tailed critical area was assumed.

Appropriate structural indicators, i.e. prevalence of a given trait expressed in percentage terms, were applied in the description of qualitative features in the examined group of affected patients and the control group. The arithmetic mean (M) was calculated to describe the value of average quantitative features. The range of values (with the minimum and maximum value determined) and the standard deviation (SD) were used as measures of dispersion.

The distribution of all variables was examined with the Shapiro-Wilk test. The hypothesis on the normality of distribution was rejected. The following non-parametric tests were applied with reference to non-parametric variables for statistical comparisons between the examined groups: Pearson's χ^2^ test and the Mann-Whitney *U* test. Spearman's rank correlation coefficient was used to evaluate the correlations between the analysed variables. The significance level for all the statistical methods applied was set at *p* \< 0.05 \[[@ref23]\]. All statistical calculations were conducted using the computer software Statistica PL, version 13.1.

Results {#S3}
=======

Sociodemographic characteristics of the studied group and the information regarding the course of the underlying disease are presented in [Table I](#T1){ref-type="table"}.

###### 

Characteristics of the studied groups in terms of demographic features and the course of depression (*n* = 104)

  Parameter                       Mean ± SD or *n* (%)     ED-I (*n* = 34)       rDE (*n* = 70)
  ------------------------------- ------------------------ --------------------- ---------------------
  Age \[years\]                   48.22 ±11.56             47.36 ±9.21           50.51 ±8.63
  Women/men                       60/44 (57.70.40/42.30)   17/17 (50.00/50.00)   43/27 (61.43/38.57)
  HDRS-I                          24.24 ±6.47              23.17 ±6.33           24.61 ±6.52
  Number of depressive episodes   --                       --                    7.15 ±3.45
  Duration of disease \[years\]   6.89 ±2.53               1.71 ±1.21            9.44 ±3.65

HDRS I -- Hamilton Depression Rating Scale on the day of qualification for the experiment, HDRS II -- Hamilton Depression Rating Scale after response to the pharmacological treatment applied, ED-I -- patients diagnosed with the first depressive episode, rDE -- patients treated for recurrent depressive episodes.

Descriptive statistics of the analysed variables {#S3_1}
------------------------------------------------

Statistically significant differences between the analysed groups in the intensity of the symptoms measured with the neurotic triad for the MMPI-2 test were confirmed. Significantly higher results were recorded by the patients hospitalised due to another episode of depression ([Table II](#T2){ref-type="table"}), which indicates the intensification of personality traits associated with anxiety reaction together with subsequent episodes of the disease. Statistically significant differences in the expression at the mRNA and the protein level were observed only for MMP-2 ([Table II](#T2){ref-type="table"}).

###### 

Descriptive statistics for the analysed variables as divided into examined groups

  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Variable                   All subjects (*n* = 104)\                                                                                                                                                                                         ED-I (*n* = 34)\   rDE (*n* = 70)\   ED-I vs. rDE    
                             Mean ± SD                                                                                                                                                                                                         Mean ± SD          Mean ± SD                         
  -------------------------- ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ------------------ ----------------- --------------- ---------
  Hypochondria scale (Hd)    High scores mean: unspecified physical problems, concern for own health, concentration on unreal somatic problems, energy deficiency, lack of satisfaction, problems with sleep, complaining, claiming attitude   71.81 ±12.86       67.01 ±11.52      74.11 ±12.91    0.012\*

  Depression scale (D)       High scores mean: depressive mood, low self-esteem and the feeling of being inappropriate, worrying, lack of satisfaction with life status, withdrawal                                                            77.31 ±11.39       73.15 ±10.13      79.29 ±11.49    0.011\*

  Hysteria scale (Hy)        High scores mean: poor insight into life-related problems and emotions, various somatic fears, problems with sleep, negation, claiming attitude, self-concentration                                               71.35 ±12.76       65.84 ±12.37      73.98 ±12.18    0.001\*

  MnSOD mRNA (2^--ΔΔct^)                                                                                                                                                                                                                       0.537 ±0.17        0.514 ±0.21       0.547 ±0.15     0.796

  MnSOD protein \[pg/ml\]                                                                                                                                                                                                                      170.57 ±63.25      166.23 ±76.36     172.35 ±57.38   0.731

  MPO mRNA (2^--ΔΔ*ct*^)                                                                                                                                                                                                                       0.319 ±0.04        0.321 ±0.04       0.318 ±0.04     0.844

  MPO protein \[ng/ml\]                                                                                                                                                                                                                        313.32 ±40.49      315.71 ±33.78     312.33 ±43.23   0.834

  COX-2 mRNA (2^--ΔΔ*ct*^)                                                                                                                                                                                                                     0.237 ±0.04        0.241 ±0.03       0.235 ±0.04     0.409

  COX-2 protein \[ng/ml\]                                                                                                                                                                                                                      113.69 ±21.56      116.47 ±20.67     112.55 ±22.01   0.491

  iNOS mRNA (2^--ΔΔ*ct*^)                                                                                                                                                                                                                      0.102 ±0.02        0.11 ±0.02        0.10 ±0.02      0.623

  iNOS protein \[ng/ml\]                                                                                                                                                                                                                       20.73 ±8.51        21.85 ±9.49       20.27 ±8.13     0.749

  MMP-2 mRNA (2^--ΔΔ*ct*^)                                                                                                                                                                                                                     284.27 ±9.35       287.16 ±9.34      282.97 ±9.13    0.039\*

  MMP-2 protein \[ng/ml\]                                                                                                                                                                                                                      363.51 ±20.52      364.87 ±22.28     358.48 ±21.51   0.133

  MMP-9 mRNA (2^--ΔΔ*ct*^)                                                                                                                                                                                                                     291.96 ±11.02      293.55 ±12.01     291.25 ±10.56   0.423

  MMP-9 protein \[ng/ml\]                                                                                                                                                                                                                      360.46 ±21.84      364.87 ±22.28     358.48 ±21.51   0.186
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

ED-I -- first depressive episode, rDE -- recurrent depressive episodes, SD -- standard deviation,\*p statistically significant, MnSOD -- manganese superoxide dismutase, MPO -- myeloperoxidase, COX-2 -- cyclooxygenase 2, iNOS -- inducible nitric oxide synthase, MMP-2 -- metalloproteinase 2, MMP-9 -- metalloproteinase 9.

Correlations {#S3_2}
------------

Results of Spearman's rank correlation for the examined groups are presented in [Table III](#T3){ref-type="table"}. The most statistically significant correlations were observed in the patients with another episode of depression compared to those treated for the first time. Scales for the neurotic triad of the MMPI-2 test correlated significantly with the expression at the level of mRNA and protein for MnSOD, MPO and metalloproteinases 2 and 9. Red also indicates correlations close to statistical significance. The absence of significant correlations in the ED-I group may be due to its low size.

###### 

Results of Spearman's rank correlation for the variables analysed

  Variable                   All subjects (*N* = 104)   ED-I (*N* = 34)   rDE (*N* = 70)                                 
  -------------------------- -------------------------- ----------------- ---------------- --------- --------- --------- ---------
  MnSOD mRNA (2^--ΔΔ*ct*^)   & Hypochondria             --0.226           0.056            --0.022   0.923     --0.311   0.026\*
  & Depression               --0.207                    0.082             --0.033          0.887     --0.310   0.027\*   
  & Hysteria                 --0.162                    0.175             --0.082          0.725     --0.264   0.062     
  MnSOD protein \[pg/ml\]    & Hypochondria             --0.229           0.053            --0.024   0.916     --0.324   0.020\*
  & Depression               --0.168                    0.159             --0.001          0.996     --0.257   0.068     
  & Hysteria                 --0.151                    0.204             --0.063          0.787     --0.257   0.069     
  MPO mRNA (2^--ΔΔ*ct*^)     & Hypochondria             0.222             0.060            0.188     0.414     0.257     0.068
  & Depression               0.136                      0.254             0.189            0.412     0.131     0.359     
  & Hysteria                 0.220                      0.064             0.104            0.655     0.255     0.071     
  MPO protein \[ng/ml\]      & Hypochondria             0.245             0.038\*          0.203     0.377     0.284     0.044\*
  & Depression               0.155                      0.193             0.226            0.325     0.153     0.285     
  & Hysteria                 0.233                      0.049             0.109            0.639     0.276     0.049\*   
  COX-2 mRNA (2^--ΔΔ*ct*^)   & Hypochondria             0.013             0.913            0.101     0.663     0.096     0.502
  & Depression               0.116                      0.334             0.407            0.067     0.089     0.536     
  & Hysteria                 0.006                      0.959             --0.024          0.917     0.036     0.804     
  COX-2 protein \[ng/ml\]    & Hypochondria             0.050             0.675            0.033     0.887     0.103     0.470
  & Depression               0.152                      0.203             0.432            0.051     0.113     0.429     
  & Hysteria                 0.051                      0.672             0.088            0.703     0.059     0.681     
  iNOS mRNA (2^--ΔΔ*ct*^)    & Hypochondria             0.139             0.244            0.247     0.281     0.106     0.460
  & Depression               0.013                      0.911             0.006            0.980     0.023     0.872     
  & Hysteria                 0.129                      0.279             0.347            0.123     0.052     0.717     
  iNOS protein \[ng/ml\]     & Hypochondria             0.095             0.426            0.233     0.310     0.059     0.681
  & Depression               0.003                      0.977             0.016            0.946     0.002     0.991     
  & Hysteria                 0.104                      0.384             0.349            0.122     --0.025   0.861     
  MMP-2 mRNA (2^--ΔΔ*ct*^)   & Hypochondria             --0.097           0.349            --0.070   0.718     --0.059   0.635
  & Depression               --0.128                    0.217             --0.040          0.837     --0.064   0.612     
  & Hysteria                 --0.169                    0.102             --0.071          0.713     --0.093   0.458     
  MMP-2 protein \[ng/ml\]    & Hypochondria             --0.186           0.072            --0.180   0.350     --0.159   0.202
  & Depression               --0.301                    0.003\*           --0.155          0.423     --0.319   0.009\*   
  & Hysteria                 --0.228                    0.027\*           --0.319          0.092     --0.131   0.294     
  MMP-9 mRNA (2^--ΔΔ*ct*^)   & Hypochondria             0.024             0.817            --0.042   0.831     0.059     0.637
  & Depression               --0.150                    0.146             --0.137          0.479     --0.142   0.254     
  & Hysteria                 0.035                      0.736             --0.165          0.392     0.142     0.254     
  MMP-9 protein \[ng/ml\]    & Hypochondria             --0.176           0.089            --0.108   0.579     --0.164   0.189
  & Depression               --0.323                    0.001\*           --0.295          0.121     --0.300   0.014\*   
  & Hysteria                 --0.122                    0.237             --0.076          0.693     --0.077   0.538     

ED-I -- first depressive episode, rDE -- recurrent depressive episodes,\*p statistically significant, MnSOD -- manganese superoxide dismutase, MPO -- myeloperoxidase, COX-2 -- cyclooxygenase 2, iNOS -- inducible nitric oxide synthase, MMP-2 -- metalloproteinase 2, MMP-9 -- metalloproteinase 9.

Discussion {#S4}
==========

To our knowledge, this is the first study to systematically investigate the roles of peripheral gene expression for indicators of inflammation and oxidative balance in personality traits predisposing to a depressive episode. In our previous papers we referred to oxidative and antioxidative imbalances and immune system disorders in patients with symptoms of depression and among healthy people: MnSOD \[[@ref24]\], MPO \[[@ref25]\], COX-2 \[[@ref26]\], iNOS \[[@ref27]\], MMP-2 and MMP-9 \[[@ref28]\]. At this point, we would like to summarise the correlations related to the functioning of the immune and emotional systems.

The affective and rational system -- the basis for personality formation {#S4_1}
------------------------------------------------------------------------

Negative emotional attitudes, typical of patients with symptoms of depression, are most likely the result of an imbalance between "emotional" (structures of the limbic system with the amygdala and the hippocampus) and "motivational/regulatory" brain regions (frontal lobes, mainly the area of the prefrontal cortex of the brain) \[[@ref29]\]. In response to negative stimuli the "emotional" brain of the individuals suffering from depression is excessively active, whereas its reaction to positive information is insufficient. On the other hand, the "motivational/regulatory" brain does not cope well with blocking and filtering unwanted and unpleasant information \[[@ref30]\]. The described dysfunctions seem to be a permanent feature of the cognitive and emotional functioning of patients with depression. They are also likely to cause a pessimistic style of information processing (as a permanent feature of personality), characteristic for people with depressive disorders, associated with numerous ruminations of a negative emotional nature \[[@ref31]\]. Thus, the cerebral cortex, by deciding how to deal with primary emotions coming from deeper structures, is responsible for the foundations of our personality.

Emotional immunity or immune emotionality? The key to understanding depression {#S4_2}
------------------------------------------------------------------------------

The dysregulation of the immune system as an aetiological factor, but also affecting the course of depression, is no longer questionable \[[@ref32], [@ref33]\]. D'Acquisto \[[@ref34]\] uses the term affective immunology. In his opinion, it means that the immune and affective systems are dynamic systems, subject to constant changes, but constituting the mirror reflection of one another. The interaction between the immune system and emotions is evidenced by the frequency of emotional disorders in patients with immune system diseases and deterioration of the immune system in patients with various groups of mental disorders \[[@ref35]\]. D'Acquisto stresses that the variability of the two systems is expressed in their plasticity, understood as the ability to change (adapt) under the influence of extrinsic factors. Both in the case of the immune system and the affective system, by means of changes in the DNA chain, we obtain from our ancestors only a biological predisposition determining the risk of incidence of a given disease. Our ability to adapt (diet, lifestyle, but also our ability to cope) determines whether or not the disease manifests itself. D'Acquisto also introduces the concept of immunological personality, asking the question of its convergence with psychological personality. It seems that the answer to this question may be in the affirmative. The personality trait important for the activation of the immune system is neuroticism, which mediates the psychological response to stress stimuli \[[@ref34]\]. [Table IV](#T4){ref-type="table"} shows the relationships described in the literature between personality traits and the indicators of an active inflammatory process \[[@ref20], [@ref36]--[@ref43]\].

###### 

Inflammatory process indicators and personality traits

  --------- --------------------------------------------------------
  ↑ IL-1    ↑ Hypochondria\
            ↑ Hysteria\
            ↑ Depression\
            ↑ Welsh's anxiety \[[@ref20]\]

  ↑ IL-6    ↑ Neuroticism \[[@ref37]\]\
            ↓ Conscientiousness \[[@ref37]\]\
            ↓ Openness to experience \[[@ref38]\]\
            ↑ Impulsiveness \[[@ref36]\]

  ↑ IL-10   ↑ Hypochondria\
            ↑ Hysteria\
            ↑ Depression\
            ↑ Welsh's anxiety \[[@ref20]\]

  ↑ IL-12   ↑ Hypochondria\
            ↑ Hysteria\
            ↑ Depression\
            ↑ Welsh's anxiety \[[@ref20]\]

  ↑ CRP     ↑ Neuroticism \[[@ref37]\]\
            ↓ Conscientiousness \[[@ref36]\]\
            ↓ Openness to experience \[[@ref39]\]\
            ↑ Hostility \[[@ref40]\]\
            ↑ Impulsiveness \[[@ref36]\]\
            ↑ Anxious attitude in reality evaluation \[[@ref43]\]\
            ↓ Self-control \[[@ref43]\]

  ↑ TNF-α   ↑ Hostility \[[@ref41], [@ref42]\]
  --------- --------------------------------------------------------

Early childhood experiences and personality traits {#S4_3}
--------------------------------------------------

Many authors stress the importance of early childhood experiences, especially those with trauma traits, for the development of mental disorders in adult life. We can find papers indicating a direct connection between trauma from childhood and abuse of psychoactive substances, psychosis, mood disorders, anxiety disorders and the risk of attempted suicide \[[@ref44]\]. These experiments lead to changes in the reactivity of the hormonal system and immune system, to changes in brain function (mainly in the frontal cortex and the hippocampus area) and, at the psychological level, to the persistence of non-adaptive ways of reacting to stressors \[[@ref45]\]. In mood disorders, early lifetime trauma is associated with increased inflammatory, as measured with CRP, and nitro-oxidative stress \[[@ref46]\]. The latter is based on pathways of nervous connections reinforced by repeating sensory experiences, both those of positive and traumatic character. Creating and reinforcing nervous connections is a key task in the early stages of brain development and forms the foundations of personality.

A particularly important need for each of us is the need for a relationship with another person. It is just as important to us as the need to satisfy hunger and thirst. Loneliness strongly motivates us to change this state \[[@ref47]\]. Insufficient satisfaction of the need for proximity in the early stages of a child's life (e.g. due to social isolation, low parental skills, emotional rejection of the child by parents) leads to changes in neurobehavioural responses to experienced stress, which shape patterns of our future relationships with people \[[@ref48]\]. This forms a depressive attitude when there is no response to an attempt to satisfy the need, and when there is frustration not only in terms of the psychological response but also in terms of the immune response. It may turn out that subsequent unsuccessful attempts at satisfying a specific problem (crying, screaming) will be considered too burdensome by the child, and hence will shape the passive attitude. Such behaviour influences the development of the immune response; when mobilisation of the body becomes too burdensome, the body reacts with no mobilisation, which explains to some extent the reduced immunity in people with depression and the occurrence of a depressive reaction in people with the diagnosis of autoimmune diseases. At the same time, the hormonal and immune systems are deregulated through the network of mutual feedback in the hypothalamic-pituitary-adrenal axis (HPA axis). A confirmation of the interaction of these systems, not only from the developmental point of view, but also from the perspective of occurrence of symptoms, is the convergence of the frequency of occurrence of both mental disorders (anxiety disorders, mood disorders) and autoimmune disorders (rheumatoid arthritis, Sjögren syndrome, multiple sclerosis), which takes place between 30 and 50 years of age \[[@ref49], [@ref50]\].

Moreover, through epigenetic mechanisms, these patterns may be passed on to future generations. This relationship was confirmed by Saavedra-Rodríguez and Feig \[[@ref51]\]. In the latter study, male and female mice were subjected to social stress during their early childhood and adolescence, in the form of instability and the need to fight for social position. These factors not only changed the anxiety behaviours of the animals examined, but were also passed on to the next three generations through epigenetic changes. Curzytek *et al*. \[[@ref52]\] reported that "pessimism" in animal models is associated with an inflammatory response as indicated by increased production of IL-1β, IL-4 and IFN. In the studies by Koutra *et al*. \[[@ref53]\], it was demonstrated that the severity of postnatal depression symptoms in the mother and the degree of anxiety she experienced as a permanent feature of her personality were related to the quality of neuropsychological development in children. Emotional proximity between parents and children during early childhood was a factor significantly affecting the cortex volume in the offspring's frontal gyrus area and correlated with personality traits conducive to depression in children \[[@ref54]\]. Interestingly, changes were observed at the micro-RNA level and in the expression of genes in reproductive cells of males affected by short-term but severe stress stimuli \[[@ref55]\]. These changes co-existed and correlated with anxiety behaviour found in these individuals. Similar epigenetic modifications were found in the brains of their offspring, which were not themselves subjected to stress stimuli.

Summary {#S4_4}
-------

When analysing the relationship between personality traits and the immune system, it is worth considering whether the traits of our personality define our later diseases in an unchangeable way, being a kind of a life sentence, over which we have no influence. Are people with neurotic features doomed to evolutionary failure? It turns out that for thousands of years of the human race's development, the anxious attitude has been conducive to survival. Our ancestors were more vigilant and focused on anticipating potential threats, which allowed them to avoid risks more effectively. Today, in an environment that is objectively assessed as low risk, a neurotic person will continue to be overly vigilant, consuming his or her immune resources pointlessly \[[@ref56]\]. In this pessimistic approach, however, it turns out that the level of intelligence is a mediator and a specific protective factor between the neurotic trait and the risk of depression \[[@ref57]\]. Therefore, the maturity of the frontal lobes, strengthening their development and improvement of their functioning should be the therapeutic goal, regarding both pharmacotherapy and psychotherapy. However, the influence of personality is only one side of the coin. The question of how the immune system influences the formation of personalities and whether this path can be a new aspect in the treatment of depression is still open. Many researchers stress the impact of the inflammatory process, which is associated both with stress in the form of pathogens and with the onset of psychological stress. The answer may be contained in the immune system's response to the stress stimulus, i.e. its ability to cope or not. The influence of oxidative factors at early stages of development may lead to epigenetic changes related to a decreased ability to mobilise the body, which leads to a prolonged inflammatory reaction. This aspect of looking at the development of depression could, for example, explain why some people with diabetes will experience a depressive episode and others will not. However, this direction of studies on the development of depressive disorders still requires a lot of research and analysis, which may contribute to new ways of treatment, especially of recurrent depressive disorders.

The obtained data indicate that an increase of the size of the studied group may be important for the accuracy of the results.

In conclusion, scales for the neurotic triad of the MMPI-2 test correlate significantly with the expression at the level of mRNA and protein for MnSOD, MPO and metalloproteinases 2 and 9 in the group of patients with symptoms of depression.
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